NCT01342497Unknown2 期
A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabetic Patients With Complicated Skin Ulceration on the Foot (Diabetic Foot Ulcer)
Bridge BioResearch Ltd.11 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 11
- 主要终点
- Rate of healing of diabetic foot ulcers (% reduction in area from baseline)
研究概览
简要总结
The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes mellitus
- •Ischaemic or neuro-ischaemic Diabetic Foot Ulcer below the malleolus, but not wholly on the sole of the foot (minimum size: 1 cm x 1 cm)
- •Body Mass Index(BMI) ≤40 kg/m2
- •Women of childbearing potential must use acceptable methods of birth control
- •Written informed consent to participate in the study
- •Patients must be able to speak English fluently and to understand English
排除标准
- •Any uncontrolled illnesses (e.g. active malignancy, vasculitis) that, in the opinion of the investigator, would interfere with interpreting the results of the study
- •Infected Diabetic Foot Ulcer based on the IDSA guidelines, i.e. presence of purulent secretions or at least two of the manifestations of inflammation (erythema, warmth, swelling or induration and pain or tenderness), and for whom, in the investigator's judgment, intravenous or oral antibiotic therapy is required
- •Active osteomyelitis
- •Wholly plantar Diabetic Foot Ulcer
- •Suspected gangrenous tissue of the affected limb that cannot be removed with a single debridement
- •Diabetic Foot Ulcer associated with prosthetic material or a device
- •Received any potentially effective systemic antibiotic therapy for more than 24 hours during the 72-hour period before the screening visit
- •Is receiving, or has received within the 14 days prior to the screening visit, any concomitant topical wound therapy (e.g., topical antimicrobial therapy, topical debriding agent, topical growth factor, topical skin replacement, or hyperbaric oxygen)
- •Has received systemic corticosteroids, immunosuppressive agents, radiation therapy or chemotherapy within the 30 days prior to the screening visit.
- •Hepatic impairment, renal impairment (defined as estimated glomerular filtration rate <10 mL/minute/1.73m2), hypersensitivity to isoniazid.
- •High risk for tuberculosis, e.g. HIV positive, are immunosuppressed, or have active malignancy
- •Symptoms of active or latent tuberculosis (based on specific history, physical examination, Interferon Gamma Release Assay (IGRA) test and chest X-Ray)
- •Known or suspected drug or alcohol abuse or positive drugs of abuse test.
- •Participating in any clinical study the 12 weeks before the screening visit
- •Donation of more than 450 mL of blood in the 3 months before the screening visit, or 1200 mL blood in the 12 months before the screening visit.
- •History of severe hypersensitivity or ongoing hypersensitivity that might affect the patient's suitability for the study (e.g. hypersensitivity to wound dressings), as judged by the investigator.
- •History of allergy to, or insensitivity to, local anaesthetics
- •Use of any prescribed or non-prescribed (over-the-counter) medication, including herbal medication (e.g., St. Johns Wort) that could possibly interfere with the objectives of this study (e.g., could affect the closure of chronic dermal ulceration), during 2 weeks (or 5 half-lives of the compound whichever is the longer) before the anticipated first dose of study medication. Occasional paracetamol for pain relief (maximum 2 g per 24 hours) and adrenergic nasal spray for relief of nasal congestion are allowed
- •Having received BBR-012 or isoniazid within the 6 months prior to the screening visit
- •Bleeding disorder or history of increased bleeding
研究组 & 干预措施
BBR-012
Experimental
干预措施: isoniazide (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Rate of healing of diabetic foot ulcers (% reduction in area from baseline)
时间窗: 4, 8 and 12 weeks
次要结局
- Rate of healing (change from baseline) as assessed by various scoring criteria: IDSA, modified ASEPSIS score, TEXAS Diabetic wound score, composite severity score and global clinical assessment(week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up))
- Effect of BBR-012 on the level of ischemia (change from baseline as measured by tcpO2)(4, 8 and 12 weeks)
- Effect of BBR-012 on microbiological outcome (presence of pathogens and outcome as compared to baseline)(week 1, 2, 3, 4, 6, 8, 10, 12 and 13-14(follow up))
- Safety and tolerability of BBR-012 as assessed by reported adverse events and safety laboratory parameters(from baseline visit to week 14)
研究者
研究点 (11)
Loading locations...
相似试验
撤回
2 期
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer PatientsLiver FibrosisHEPATITIS B CHRONICHepatocellular CarcinomaNCT02289300A2 Healthcare Taiwan Corporation
终止
2 期
Study of BIIB092 in Participants With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveNCT03068468Biogen490
撤回
2 期
Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic EpilepsyPost-traumatic EpilepsyNCT06523725Dr. Paul Lyons50
招募中
2 期
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerTriple-negative Breast CancerNCT06471205Sichuan Baili Pharmaceutical Co., Ltd.52
招募中
2 期
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsSolid TumorNon-small Cell Lung CancerNasopharyngeal CarcinomaNCT06475300Sichuan Baili Pharmaceutical Co., Ltd.570